Boston Scientific trial shows benefits of Synergy stent

Boston Scientific has reported data from a new clinical study of Synergy, its new everolimus-eluting stent system for treating de novo coronary artery lesions.

The medical device has had its effectiveness evaluated in Evolve, the first human use trial to compare the performance of Synergy to the company's own Promus Element stent.

Analysis of 30-day and six-month trial data showed that the newer device was able to deliver a comparable performance in terms of safety and efficacy to Promus Element, which is already commercially available.

This meant Synergy was able to meet its primary endpoint goal in the trial, while it was also associated with very low rates of myocardial infarction and revascularisation and zero cardiac deaths or stent thrombosis incidents.

Dr Keith Dawkins, senior vice-president and chief medical officer of Boston Scientific's cardiology, rhythm and vascular group, said: "Evolve trial data will be used to support CE Mark approval for Synergy, while additional larger studies are planned to further assess clinical event rates and the potential for reduced dual antiplatelet therapy."

This week also saw the company report positive data from a new study of its new PolarCath dilation system.